• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).
Conclusion: The GARDEN study was set up to tackle a global Public Health emergency. Glenzocimab was safe in doses three times higher than used in stroke. Albeit efficacy was not shown, overall, GARDEN provides insights into Cov-ARDS.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Pottecher, J., Sato, V. A. H., Pletan, Y., Comenducci, A., Desort-Henin, V., Jandrot-Perrus, M., Binay, S., Meilhoc, A., Avenard, G. Tags: 02.01 - Acute critical care Source Type: research

Utilization and Outcomes of Acute Revascularization Treatment in Ischemic Stroke Patients with SARS-CoV-2 Infection
Our understanding of outcomes in acute ischemic stroke patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following acute revascularization treatments (as intravenous thrombolysis and/or thrombectomy) is based on small case series.1-3. An international panel4 cautioned regarding the potential for high rate of death or disability and post thrombolytic intracerebral hemorrhage (ICH)s in acute ischemic stroke patients with SARS-CoV-2 infection due to elevated concentrations of inflammation and hypercoagulability markers such as leukocytosis, and C reactive protein and D dimers and multisystem dysfunction.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2021 Category: Neurology Authors: Adnan I. Qureshi, William I. Baskett, Wei Huang, Muhammad F. Ishfaq, S. Hasan Naqvi, Brandi R. French, Farhan Siddiq, Camilo R. Gomez, Chi-Ren Shyu Tags: SARS-CoV-2 and acute revascularization Source Type: research

Utilization and Outcomes of Acute Revascularization Treatments in Ischemic Stroke Patients with SARS-CoV-2 Infection
Our understanding of outcomes in acute ischemic stroke patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following acute revascularization treatments (as intravenous thrombolysis and/or thrombectomy) is based on small case series.1 –3 An international panel4 cautioned regarding the potential for high rate of death or disability and post thrombolytic intracerebral hemorrhage (ICH)s in acute ischemic stroke patients with SARS-CoV-2 infection due to elevated concentrations of inflammation and hypercoagulability markers such as leukocytosis, and C reactive protein and D dimers and multisystem dysfunction.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2021 Category: Neurology Authors: Adnan I. Qureshi, William I. Baskett, Wei Huang, Muhammad F. Ishfaq, S. Hasan Naqvi, Brandi R. French, Farhan Siddiq, Camilo R. Gomez, Chi-Ren Shyu Source Type: research

Pathogeny of cerebral venous thrombosis in SARS-Cov-2 infection: Case reports
We describe 2 cases of women admitted during the spring of 2020 for intracranial hypertension signs, in stroke units in Great-east, a French area particularly affected by COVID-19 pandemia. Diagnoses: Cerebral imaging revealed extended CVT in both cases. The first case described was more serious due to right supratentorial venous infarction with hemorrhagic transformation leading to herniation. Both patients presented typical pneumonia due to SARS-Cov-2 infection, confirmed by reverse transcription polymerase chain reaction on a nasopharyngeal swab in only one. Interventions: The first patient had to undergo ...
Source: Medicine - March 12, 2021 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research